Cassava Sciences, Inc.
NASDAQ: SAVA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard Jon Barry
- Employees
- 30
- Headquarters
- Austin, United States
- IPO year
- 2000
- Market cap
- $63.8M
- Website
- https://www.cassavasciences.com
Loading SAVA…
Loading profile data…Frequently asked questions about SAVA
What does Cassava Sciences, Inc. (SAVA) do?
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an...
Where does SAVA trade?
Cassava Sciences, Inc. (SAVA) trades on the NASDAQ Capital Market.
What sector is SAVA in?
Cassava Sciences, Inc. (SAVA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cassava Sciences, Inc.?
Richard Jon Barry is the chief executive officer of Cassava Sciences, Inc. (SAVA).
Where is Cassava Sciences, Inc. headquartered?
Cassava Sciences, Inc. is headquartered in United States.
Does SAVA pay a dividend?
Cassava Sciences, Inc. (SAVA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SAVA go public?
Cassava Sciences, Inc. (SAVA) completed its initial public offering in 2000.